Bernard Lieb

Title: Bernard Lieb: Innovator in Nucleic Acid Technology

Introduction

Bernard Lieb is a notable inventor based in Mainz, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of nucleic acid molecules.

Latest Patents

Lieb holds a patent for a nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin. This invention includes a nucleic acid molecule or construct that codes for a HLH2 haemocyanin polypeptide and comprises at least one intron sequence. Additionally, it encompasses haemocyanin fusion proteins and can include a nucleic acid sequence that codes for an antigen. The invention also considers host cells that contain the nucleic acid molecules or constructs and the recombinant expression products thereof. Furthermore, it relates to a pharmaceutical composition that includes the expression product of the nucleic acid and antibodies obtainable by immunization of an animal, as well as the use of these antibodies in screening methods for tumor identification.

Career Highlights

Bernard Lieb is associated with Biosyn Arzneimittel GmbH, where he continues to advance his research and innovations in biotechnology. His work has the potential to impact various medical applications, particularly in cancer diagnostics and treatment.

Collaborations

Lieb has collaborated with notable colleagues, including Jürgen Markl and Benjamin Altenhein, contributing to the advancement of their shared research goals.

Conclusion

Bernard Lieb's innovative work in nucleic acid technology exemplifies the significant advancements being made in biotechnology. His contributions are paving the way for new medical solutions and enhancing our understanding of genetic applications.